×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Leap Therapeutics Announces $40 Million Private Placement
PR Newswire
PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology...
1 month ago
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024
MSN
LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
2 days ago
Analyst Estimates: Here's What Brokers Think Of Leap Therapeutics, Inc. (NASDAQ:LPTX) After Its First-Quarter Report
Yahoo News New Zealand
Leap Therapeutics, Inc. (NASDAQ:LPTX) missed earnings with its latest quarterly results, disappointing...
2 days ago
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst
Seeking Alpha
Leap Therapeutics is developing DKN-01, a drug with potential in multiple types of cancer. Read my earnings analysis of LPTX stock here.
1 week ago
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update
Defense World
Read Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update at Defense World.
1 week ago
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024
MSN
LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.More From InvestorPlace The #1 AI...
2 days ago
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Yahoo Finance
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
2 months ago
Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
4 days ago
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal ...
PR Newswire
The DeFianCe study (NCT05480306) is a Phase 2, open-label, global study of DKN-01 in combination with standard of care bevacizumab and...
4 months ago